Imv Inc (IMV)

1.91
-0.06(-3.05%)
  • Volume:
    55,150
  • Bid/Ask:
    1.89/1.91
  • Day's Range:
    1.88 - 1.97
  • Type:Equity
  • Market:Canada
  • ISIN:CA44974L1031
  • CUSIP:44974L103

IMV Overview

Prev. Close
1.97
Day's Range
1.88-1.97
Revenue
315.67K
Open
1.95
52 wk Range
1.68-5.86
EPS
-0.51
Volume
55,150
Market Cap
156.89M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
154,071
P/E Ratio
-
Beta
1.86
1-Year Change
-59.87%
Shares Outstanding
82,142,629
Next Earnings Date
Nov. 11, 2021
What is your sentiment on Imv Inc?
or
Market is currently closed. Voting is open during market hours.

Imv Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong SellStrong SellStrong SellStrong Sell
SummaryNeutralStrong SellStrong SellStrong SellStrong Sell

Imv Inc Company Profile

Imv Inc Company Profile

Sector
Services
Employees
77
Market
Canada

IMV Inc. is a clinical stage biopharmaceutical company focused on developing cancer immunotherapies and vaccines against infectious diseases, including coronavirus disease 2019 (COVID-19). The Company develops cancer-targeted immunotherapies and vaccines based on the Company’s platform, DPX. The Company’s lead candidate, DPX-Survivac, is a T cell-activating immunotherapy that combines the platform with a cancer target: survivin. Its T cell therapy is evaluated in phase II clinical trials in ovarian cancer and in combination with Merck's Keytruda across multiple cancer indications. Its T cell therapy, DPX-Survivac, consists of survivin-based peptides formulated in its platform (DPX). DPX-Survivac is designed to generate a cytotoxic T cell response against cancer cells offering survivin peptides on their surface.

Read More
  • I agree with you Rodney.
    1
    • This company is now doing human tests with a possible COVID-19 vaccine. If it works, watch the value of this stock go up substantially.
      1
      • will go up to 16$ by December.
        0
        • $16 before December .
          0
      • this is gonna go up to 8$ really soon but I doubt its gonna pass 10$ after Q2 earning. This is a great stocks under 10$ right now.
        1
        • Nice prediction
          0
        • thank you should I keep it or sell at what price is best ?
          0
        • Hold, dont sell. It will shoot up soon.
          0
      • any good stock under 10$ canada or us???
        0
        • this company is a hold, amazing work amazing team good job
          1
          • really? company makes almost no capital, has massive expenditures in a sector that is subject to huge govt intervention. wouldn't touch this with a 10 foot pole (or MAYBE a discounted price if financials come back around.) you are buying into a company that doesnt make money.
            0
          • I do agree with you Jeff but some people just trade the stock, some invest in these pharmaceuticals because they believe in their products. Just take what you can from these pharma stocks, I usually ride the waves on their clinical trials before FDA...these pharma stocks are not for everyone lol gotta have balls of steel if people hold while FDA is making the decision and stocks halted. But some do pay off if they hit. Happy trading 🤓
            0
        • Anything under 10 is buy imo. Buy into companies you believe in is some great advice I got once. This I believe in!
          1
          • Anything under 10 is buy imo. Buy into companies you believe in is some great advice I got once. This I believe in!
            0
            • Anything under 10 is buy imo. Buy into companies you believe in is some great advice I got once. This I believe in!
              0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.